Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...

Additionally, a supportive secondary analysis showed that 50.7% of participants with obesity treated with CagriSema reached non-obesity levels (BMI 30 kg/m²) by the end of treatment, down from a mean ...

Experts said that the novel combination of a GLP-1 and amylin analogue will help obese patients with and without diabetes ...

Nasdaq listing, but overvaluation concerns highlight profit-taking opportunity. Check out why we rate BGL stock as Sell.

Modifiable lifestyle factors significantly affect the incidence of psoriatic disease, cardiometabolic comorbidities, and all-cause mortality.

Earlier in May, in an attempt to curb an increase in type 2 diabetes in children, the Central Board of Secondary Education ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

Background Immune-mediated processes leading to childhood type 1 diabetes may begin in fetal life. We hypothesised that a ...

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...

In a study of adults with diabetes and gastrointestinal (GI) motility abnormalities, over 75% had GI motility abnormalities.